FDA Panel Rejects Merck Statin Mevacor For OTC Status

An FDA advisory panel on Thursday voted 10-2 against recommending that Merck’s cholesterol drug Mevacor be granted over-the-counter status, the Philadelphia Inquirer reports. [click link for full article]

More: continued here

Filed under: Statins on December 20th, 2007